We are leading formulations player engaged in the development, manufacture, sale, and distribution of proprietary generic pharmaceutical products principally in the United States, and with a growing presence in Europe, Canada, Japan, Australia and the rest of the world.

It is Jubilant’s endeavour to develop affordable generics with best quality.

The generics business is vertically integrated into our APIs business and emphasizes on manufacturing and sale of proprietary finished dosage formulations including CVS, CNS, GI, anti-inflammatory and anti-allergy categories.


  • Multiple dosage form / containment capabilities
    • Immediate release oral solids
    • Modified release oral solids
    • Steroids
    • Oral powder for solution/suspension (POS)
    • Potential for liquids, ointments, powders, opthalmic and injectables
    • Experience in developing formulations for veterinary business
  • A leading formulations player – development, manufacture and sale of proprietary dosage formulations.
  • Creating differential dosage forms with MUPS based products, ODT, chewable tablets Powder For Oral Suspension, etc.
  • Capability of product development for vrious geographies like USA, EU, Canada, Japan, China, Australia, Brazil, and ROW Markets.
  • In-house BA BE unit inspected by USFDA and other key regulatory agencies.
  • In the United States market, since we commenced operations through to December 31, 2019, we have made a total of 98 ANDA filings for solid dosage formulations, of which 36 are pending approval.
  • As at December 2019, we had 56 commercialized generic solid dosage formulations products across the United States, Europe, Canada, Australia and the rest of the world.
  • One of the largest exporters of oral solid formulations to Japan.
  • Our in-house API capability provides us stable source of API supply for availability of these products at competitive prices.


We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.